Cyclo Therapeutics (NASDAQ:CYTH) Shares Down 1.7%

Cyclo Therapeutics, Inc. (NASDAQ:CYTHGet Free Report) fell 1.7% during trading on Friday . The company traded as low as $1.71 and last traded at $1.76. 10,499 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 105,223 shares. The stock had previously closed at $1.79.

Cyclo Therapeutics Stock Down 1.7 %

The stock has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $1.35. The company has a market cap of $33.98 million, a price-to-earnings ratio of -0.94 and a beta of -0.42.

Cyclo Therapeutics (NASDAQ:CYTHGet Free Report) last announced its quarterly earnings data on Tuesday, August 15th. The company reported ($0.33) earnings per share for the quarter. Cyclo Therapeutics had a negative net margin of 2,078.30% and a negative return on equity of 1,706.53%. The company had revenue of $0.12 million during the quarter.

Insider Transactions at Cyclo Therapeutics

In other Cyclo Therapeutics news, major shareholder Rafael Holdings, Inc. purchased 4,000,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were bought at an average price of $1.25 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider now owns 6,514,970 shares in the company, valued at approximately $8,143,712.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 29.78% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cyclo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new stake in shares of Cyclo Therapeutics during the second quarter worth $28,000. Geode Capital Management LLC raised its position in Cyclo Therapeutics by 92.1% in the second quarter. Geode Capital Management LLC now owns 100,388 shares of the company’s stock valued at $160,000 after purchasing an additional 48,135 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of Cyclo Therapeutics during the second quarter valued at about $26,000. Finally, Armistice Capital LLC bought a new stake in shares of Cyclo Therapeutics during the fourth quarter worth about $1,321,000. 23.03% of the stock is owned by institutional investors.

About Cyclo Therapeutics

(Get Free Report)

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease.

Further Reading

Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with's FREE daily email newsletter.